Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Acute lymphoblastic leukemia in children: past, present and future

소아 급성 림프모구 백혈병: 과거, 현재, 미래

  • Kang, Hyoung Jin (Department of Pediatrics, Cancer Research Institute Seoul National University College of Medicine) ;
  • Shin, Hee Young (Department of Pediatrics, Cancer Research Institute Seoul National University College of Medicine) ;
  • Ahn, Hyo Seop (Department of Pediatrics, Cancer Research Institute Seoul N)
  • 강형진 (서울대학교 의과대학 소아과학교실, 암연구소) ;
  • 신희영 (서울대학교 의과대학 소아과학교실, 암연구소) ;
  • 안효섭 (서울대학교 의과대학 소아과학교실, 암연구소)
  • Received : 2007.06.20
  • Accepted : 2007.07.05
  • Published : 2007.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

The cure rate of acute lymphoblastic leukemia (ALL) in children dramatically improved over past 5 decades from zero to about 80%. The main cause of improvement is owing to the development of chemotherapy by multicenter clinical trial of large study groups with the understanding of leukemia biology. Recently, pediatric ALL protocols were applied to the treatment of adolescent and even adult ALL patients. For nearly 30 years, clinical factors have been used to risk-stratify therapy for children with ALL, so that the most intensive therapies are reserved for those patients at the highest risk of relapse. The risk groups of ALL are divided as standard- (low- plus intermediate-), high- and very high-risk group according to the prognostic factors, and treatment results improved by this risk based treatment. The factors used to risk-stratify therapy include age, gender, presenting leukocyte count, immunophenotype, cytogenetic aberrations including ploidy and translocations, and initial response after 1 to 2 weeks of therapy. But treatment efficacy is the most important determinant and can abolish the clinical significance of most, if at all, prognostic factors. Today, in the era of intensive, multiagent regimens, there is increasing evidence that we have reached the limits of prognostic significance of currently applied clinical risk factors in childhood ALL. As the cure rate of ALL is about 80%, introducing new prognostic factors such as new molecular prognostic markers, new methods of assessment about minimal residual disease, and pharmacogenetic study, with the development of stem cell transplantation and molecular targeted therapy are needed to cure residual 20% of childhood ALL patients without short and long term complications.

Keywords

Acknowledgement

Supported by : 보건복지부

References

  1. Simone JV. Childhood leukemia-successes and challenges for survivors. N Engl J Med 2003;349:627-8 https://doi.org/10.1056/NEJMp030094
  2. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997;90:4243-51
  3. Beutler E. The treatment of acute leukemia: past, present, and future. Leukemia 2001;15:658-61 https://doi.org/10.1038/sj/leu/2402065
  4. Farber S, Diamond LK, Mercer RD. Temporary remissions in acute leukemia produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948;238:787
  5. Singh TP. Clinical trials of newly developed anti-cancer agents in children with acute leukemia. Contemp Clin Trials 2006;27:493 https://doi.org/10.1016/j.cct.2006.10.003
  6. Frei E 3rd. Acute leukemia in children. Model for the development of scientific methodology for clinical therapeutic research in cancer. Cancer 1984;53:2013-25 https://doi.org/10.1002/1097-0142(19840515)53:10<2013::AID-CNCR2820531003>3.0.CO;2-2
  7. Woodhouse JR, Ferry DR. The genetic basis of resistance to cancer chemotherapy. Ann Med 1995;27:157-67 https://doi.org/10.3109/07853899509031953
  8. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33
  9. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et. al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24 https://doi.org/10.1200/JCO.1996.14.1.18
  10. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004;:118-45 https://doi.org/10.1182/asheducation-2004.1.118
  11. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12,000 randomised children. Lancet 1996;347:1783-8 https://doi.org/10.1016/S0140-6736(96)91615-3
  12. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006 https://doi.org/10.1056/NEJM200004063421402
  13. Shin HY, Kang HJ, Park ES, Choi HS, Ahn HS, Kim SY, et al. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer 2006;46:439-45 https://doi.org/10.1002/pbc.20555
  14. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer 1998;83:2030-9 https://doi.org/10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q
  15. Hilden JM, Kersey JH. The MLL (11q23) and AF-4 (4q21) genes disrupted in t(4;11) acute leukemia: molecular and clinical studies. Leuk Lymphoma 1994;14:189-95 https://doi.org/10.3109/10428199409049668
  16. Deangelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2005;:123-30 https://doi.org/10.1182/asheducation-2005.1.123
  17. Silverman LB, Sallan SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol 2003;10:290-6 https://doi.org/10.1097/00062752-200307000-00007
  18. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133- 43 https://doi.org/10.1016/S1535-6108(02)00032-6
  19. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007;109:471-7 https://doi.org/10.1182/blood-2006-07-032557
  20. Marshall GM, Haber M, Kwan E, Zhu L, Ferrara D, Xue C, et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:704-9 https://doi.org/10.1200/JCO.2003.10.080
  21. Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15:741-56 https://doi.org/10.1053/beha.2002.0225
  22. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007;6:149-65 https://doi.org/10.1038/nrd2240